sulforaphane has been researched along with Osteoarthritis in 5 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulforaphane (SFN) is an isothiocyanate with anti-arthritic and immuno-regulatory activities, supported by the downregulation of NF-κB pathway, reduction on metalloproteinases expression and prevention of cytokine-induced cartilage degeneration implicated in OA progression." | 5.62 | Sulforaphane-loaded hyaluronic acid-poloxamer hybrid hydrogel enhances cartilage protection in osteoarthritis models. ( Alberto-Silva, C; Ambrosio, FN; Christoffolete, MA; de Araujo, DR; Ferraraz, DC; Franco, MKKD; Kent, B; Lombello, CB; Monteiro do Nascimento, MH; Nascimento-Sales, M; Querobino, SM; Windisch-Neto, H; Yokaichiya, F, 2021) |
| "Sulforaphane is a naturally occurring antioxidant." | 5.46 | Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis. ( Aljazzar, A; Chan, B; Chang, YM; de Souza, R; Hopkinson, M; Javaheri, B; Lee, PD; Orriss, IR; Piles, M; Pitsillides, AA; Pollard, A; Poulet, B; Shervill, E, 2017) |
| "Sulforaphane (SFN) is a member of the isothiocyanate family that has anti-inflammatory action as well as anti-carcinogenic properties." | 5.39 | Sulforaphane-PLGA microspheres for the intra-articular treatment of osteoarthritis. ( Choi, YJ; Im, GI; Jeong, GJ; Ko, JY, 2013) |
| "Sulforaphane (SFN) is an isothiocyanate with anti-arthritic and immuno-regulatory activities, supported by the downregulation of NF-κB pathway, reduction on metalloproteinases expression and prevention of cytokine-induced cartilage degeneration implicated in OA progression." | 1.62 | Sulforaphane-loaded hyaluronic acid-poloxamer hybrid hydrogel enhances cartilage protection in osteoarthritis models. ( Alberto-Silva, C; Ambrosio, FN; Christoffolete, MA; de Araujo, DR; Ferraraz, DC; Franco, MKKD; Kent, B; Lombello, CB; Monteiro do Nascimento, MH; Nascimento-Sales, M; Querobino, SM; Windisch-Neto, H; Yokaichiya, F, 2021) |
| "Sulforaphane is a naturally occurring antioxidant." | 1.46 | Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis. ( Aljazzar, A; Chan, B; Chang, YM; de Souza, R; Hopkinson, M; Javaheri, B; Lee, PD; Orriss, IR; Piles, M; Pitsillides, AA; Pollard, A; Poulet, B; Shervill, E, 2017) |
| "Sulforaphane (SFN) is a member of the isothiocyanate family that has anti-inflammatory action as well as anti-carcinogenic properties." | 1.39 | Sulforaphane-PLGA microspheres for the intra-articular treatment of osteoarthritis. ( Choi, YJ; Im, GI; Jeong, GJ; Ko, JY, 2013) |
| "Sulforaphane (SFN) has been reported to regulate signaling pathways relevant to chronic diseases." | 1.39 | Sulforaphane represses matrix-degrading proteases and protects cartilage from destruction in vitro and in vivo. ( Bao, Y; Clark, IM; Culley, KL; Davidson, RK; de Ferrars, R; Donell, ST; Driscoll, C; Jupp, O; Kay, CD; Norton, R; Vincent, TL, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Monteiro do Nascimento, MH | 1 |
| Ambrosio, FN | 1 |
| Ferraraz, DC | 1 |
| Windisch-Neto, H | 1 |
| Querobino, SM | 1 |
| Nascimento-Sales, M | 1 |
| Alberto-Silva, C | 1 |
| Christoffolete, MA | 1 |
| Franco, MKKD | 1 |
| Kent, B | 1 |
| Yokaichiya, F | 1 |
| Lombello, CB | 1 |
| de Araujo, DR | 1 |
| Javaheri, B | 1 |
| Poulet, B | 1 |
| Aljazzar, A | 1 |
| de Souza, R | 1 |
| Piles, M | 1 |
| Hopkinson, M | 1 |
| Shervill, E | 1 |
| Pollard, A | 1 |
| Chan, B | 1 |
| Chang, YM | 1 |
| Orriss, IR | 1 |
| Lee, PD | 1 |
| Pitsillides, AA | 1 |
| Ko, JY | 1 |
| Choi, YJ | 1 |
| Jeong, GJ | 1 |
| Im, GI | 1 |
| Davidson, RK | 1 |
| Jupp, O | 1 |
| de Ferrars, R | 1 |
| Kay, CD | 1 |
| Culley, KL | 1 |
| Norton, R | 1 |
| Driscoll, C | 1 |
| Vincent, TL | 1 |
| Donell, ST | 1 |
| Bao, Y | 1 |
| Clark, IM | 1 |
| Pal, S | 1 |
| Konkimalla, VB | 1 |
5 other studies available for sulforaphane and Osteoarthritis
| Article | Year |
|---|---|
Sulforaphane-loaded hyaluronic acid-poloxamer hybrid hydrogel enhances cartilage protection in osteoarthritis models.
Topics: Cartilage; Humans; Hyaluronic Acid; Hydrogels; Isothiocyanates; Osteoarthritis; Poloxamer; Sulfoxide | 2021 |
Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis.
Topics: Animals; Antioxidants; Arthritis, Experimental; Bone and Bones; Isothiocyanates; Lameness, Animal; M | 2017 |
Sulforaphane-PLGA microspheres for the intra-articular treatment of osteoarthritis.
Topics: Aged; Animals; Cartilage, Articular; Chondrocytes; Cytoprotection; Dose-Response Relationship, Drug; | 2013 |
Sulforaphane represses matrix-degrading proteases and protects cartilage from destruction in vitro and in vivo.
Topics: Animals; Arthritis, Experimental; Cartilage, Articular; Cattle; Chondrocytes; Humans; Isothiocyanate | 2013 |
Sulforaphane regulates phenotypic and functional switching of both induced and spontaneously differentiating human monocytes.
Topics: Anti-Inflammatory Agents; Arthritis, Experimental; Cell Differentiation; Cell Line; Collagen; Extrac | 2016 |